Literature DB >> 3772387

Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer's disease and the normal.

D D Flynn, D C Mash.   

Abstract

Putative nicotine receptors in the human cerebral cortex were characterized with L-[3H]nicotine, L-[3H]Nicotine binding was enhanced by the addition of Ca2+ and abolished in the presence of Na3EDTA. Association and dissociation of the ligand were rapid at 25 degrees C with t1/2 values of 2 and 3 min, respectively. Saturation binding analysis revealed an apparent single class of sites with a dissociation constant of 5.6 nM and a Hill coefficient of 1.05. There was no effect of postmortem interval on the density of binding sites assayed up to 24 h in rat frontoparietal cortex. Nicotine binding in human cortical samples was also unaltered by increasing sampling delay. In human cortical membranes, binding site density decreased with normal aging. Receptor affinity and concentration in samples of frontal cortex (Brodmann area 10) from patients with Alzheimer's disease were comparable to age-matched control values. Samples of infratemporal cortex (Brodmann area 38) from patients with Alzheimer's disease had a 50% reduction in the number of L-[3H]nicotine sites. Choline acetyltransferase activity was significantly decreased in both cortical areas. Enzyme activities in the temporal pole were reduced to 20% of control values. These data indicate that postsynaptic nicotine receptors are spared in the frontal cortex in Alzheimer's disease. In the infratemporal cortex, significant numbers of receptors remain despite the severe reduction in choline acetyltransferase activity. Replacement therapy directed at these sites may be warranted in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3772387     DOI: 10.1111/j.1471-4159.1986.tb13113.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

1.  Acute nicotinic blockade produces cognitive impairment in normal humans.

Authors:  P A Newhouse; A Potter; J Corwin; R Lenox
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Alterations in neocortical expression of nicotinic acetylcholine receptor mRNAs following unilateral lesions of the rat nucleus basalis magnocellularis.

Authors:  I Miyai; S Ueno; S Yorifuji; H Fujimura; S Tarui
Journal:  J Neural Transm Gen Sect       Date:  1990

Review 3.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

Review 4.  The acetylcholine receptor ligand-gated channel as a molecular target of disease and therapeutic agents.

Authors:  F J Barrantes
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

Review 5.  Molecular studies of the neuronal nicotinic acetylcholine receptor family.

Authors:  J Lindstrom; R Schoepfer; P Whiting
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

6.  Endogenously expressed muscarinic receptors in HEK293 cells augment up-regulation of stably expressed α4β2 nicotinic receptors.

Authors:  Gregory P Hussmann; Robert P Yasuda; Yingxian Xiao; Barry B Wolfe; Kenneth J Kellar
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

Review 7.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 8.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

9.  Nicotinic systems and cognitive function.

Authors:  E D Levin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Α4β2 and α7 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks.

Authors:  I A Mendez; J C Damborsky; U H Winzer-Serhan; J L Bizon; B Setlow
Journal:  Neuroscience       Date:  2012-11-14       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.